COR THERAPEUTICS' PLATELET AGGREGATION INHIBITOR
Executive Summary
COR THERAPEUTICS' PLATELET AGGREGATION INHIBITOR is being developed as a stand-alone therapy for acute thrombosis and for use with thrombolytics in acute care settings. The glycoprotein IIb-IIIa antagonist is the lead compound of COR Therapeutics, a two-year-old, privately-held cardiovascular R&D firm based in South San Francisco. COR expects to initiate human clinicals by 1992 for acute thrombosis associated with heart attacks, unstable angina, and stroke. The company's follow-on compound is a vascular growth inhibitor in development to prevent restenosis following arterial unblocking procedures such as coronary angioplasty. The product, "an antagonist to the platelet-derived growth factor receptor," may work by turning off the mechanisms responsible for the over-production of smooth muscle cells, the company explained. Merrell Dow vet Vaughn Kailian joined COR as president and CEO on March 1. Kailian, 45, succeeded co-founder and ex-Robertson Stephens general partner Lee Douglas, who has been named VP-business development. Kailian rose through the ranks at Merrell Dow to president and general manager for Merrell Dow USA prior to the company's merger with Marion Labs in 1989. He has extensive marketing and sales experience at Merrel Dow, both in the U.S. and overseas. Prior to joining COR, Kailian served as Marion Merrell Dow corporate VP of global commercial development. Other top COR management include VP-Operations and Development Robert Swift, PhD, and Nancy Montgomery, who is the acting chief financial officer. Swift spent five years as Genentech's first director of clinical affairs and before that was with Pfizer for eight years. Prior to joining COR, Montgomery was VP of finance and chief financial officer at Applied Biosystems.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth